Browse result page of CancerPDF Database
Please click on CancerPDF_ID for detailed information about peptide.
| CancerPDF_ID | Peptide seq | Protein Name | Fluid | Mass/Z | Profiling Technique | Cancer Type | Expression Regulation | PUBMED ID |
|---|---|---|---|---|---|---|---|---|
| CancerPDF_ID23 | HWESASLL | Complement C3f | Serum | 942.44 | MALDI-TOF | Metastatic thyroid carcinomas | Differentially expressed between cancer vs normal samples | 16896061 |
| CancerPDF_ID24 | IHWESASLL | Complement C3f | Serum | 1055.6 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID25 | RIHWESASLL | Complement C3f | Serum | 1211.7 | MALDI-TOF | Metastatic thyroid carcinomas | Differentially expressed between cancer vs normal samples | 16896061 |
| CancerPDF_ID26 | HRIHWESASLL | Complement C3f | Serum | 1348.7 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID27 | THRIHWESASLL | Complement C3f | Serum | 1449.76 | MALDI-TOF | Metastatic thyroid carcinomas | Differentially expressed between cancer vs normal samples | 16896061 |
| CancerPDF_ID28 | ITHRIHWESASLL | Complement C3f | Serum | 1562.84 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID29 | KITHRIHWESASLL | Complement C3f | Serum | 1690.9 | MALDI-TOF | Metastatic thyroid carcinomas | Differentially expressed between cancer vs normal samples | 16896061 |
| CancerPDF_ID30 | SKITHRIHWESASLL | Complement C3f | Serum | 1777.94 | MALDI-TOF | Metastatic thyroid carcinomas | Differentially expressed between cancer vs normal samples | 16896061 |
| CancerPDF_ID31 | SSKITHRIHWESASLL | Complement C3f | Serum | 1864.95 | MALDI-TOF | Metastatic thyroid carcinomas | Differentially expressed between cancer vs normal samples | 16896061 |
| CancerPDF_ID32 | SSKITHRIHWESASLLR | Complement C3f | Serum | 2021.06 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID33 | SSKITHRIHWESASL | Complement C3f | Serum | 1751.88 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID195 | KITHRIHWESASLL | Complement C3f | Serum | 1690.9254 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS | 19728888 |
| CancerPDF_ID196 | SKITHRIHWESASLL | Complement C3f | Serum | 1777.966 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS | 19728888 |
| CancerPDF_ID197 | SSKITHRIHWESASLL | Complement C3f | Serum | 1865.0022 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS | 19728888 |
| CancerPDF_ID205 | SKITHRIHWESASLL | Complement C3 f | Serum | 1777.966 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Differentially expressed between NSCLC patients vs healthy volunteers | 19728888 |
| CancerPDF_ID208 | KITHRIHWESASLL | Complement C3 f | Serum | 1690.9254 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Differentially expressed between NSCLC patients vs healthy volunteers | 19728888 |
| CancerPDF_ID209 | SSKITHRIHWESASLL | Complement C3 f | Serum | 1865.0022 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Differentially expressed between NSCLC patients vs healthy volunteers | 19728888 |
| CancerPDF_ID226 | SPMYSIITPNILRLESEETM | Complement C3 beta/f | Serum | 2324.1475 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Signature peptide that can Differentiate between NSCLC patients and healthy volunteers | 19728888 |
| CancerPDF_ID230 | SPMYSIITPNILRLESEET | Complement C3 beta/f | Serum | 2193.1036 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Signature peptide that can Differentiate between NSCLC patients and healthy volunteers | 19728888 |
| CancerPDF_ID923 | SSKITHRIHWESASLLR | Complement C3 | Plasma | 674.36 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID924 | SSKITHRIHWESASLL | Complement C3 | Plasma | 933.05 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID925 | SSKITHRIHWESA | Complement C3 | Plasma | 776.4 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID926 | SKITHRIHWESA | Complement C3 | Plasma | 732.88 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID927 | KITHRIHWESA | Complement C3 | Plasma | 689.36 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID928 | ITHRIHWESA | Complement C3 | Plasma | 625.32 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID929 | THRIHWESASLLR | Complement C3 | Plasma | 535.95 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID930 | THRIHWESASLL | Complement C3 | Plasma | 725.38 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID931 | THRIHWESASL | Complement C3 | Plasma | 668.83 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID932 | THRIHWESA | Complement C3 | Plasma | 568.78 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID933 | HRIHWESASLLR | Complement C3 | Plasma | 502.27 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID934 | HRIHWESASLL | Complement C3 | Plasma | 674.85 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID935 | HRIHWESASL | Complement C3 | Plasma | 618.31 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID936 | RIHWESASLLR | Complement C3 | Plasma | 456.58 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID937 | RIHWESASL | Complement C3 | Plasma | 549.78 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID938 | IHWESASLLR | Complement C3 | Plasma | 606.32 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID939 | IHWESASLL | Complement C3 | Plasma | 528.27 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID940 | IHWESASL | Complement C3 | Plasma | 471.73 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID941 | HWESASLLR | Complement C3 | Plasma | 549.78 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID942 | SEETKENEGFTVTAEGK | Complement C3 | Plasma | "928.42, 619.28" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID943 | SEETKENEGFTVTAEG | Complement C3 | Plasma | 864.38 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID944 | EETKENEGFTVTAEG | Complement C3 | Plasma | 820.86 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID945 | TKENEGFTVTAEGK | Complement C3 | Plasma | 755.86 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID946 | ENEGFTVTAEGK | Complement C3 | Plasma | 641.29 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID947 | NEGFTVTAEGK | Complement C3 | Plasma | 576.77 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID948 | TLDPERLGR | Complement C3 | Plasma | 528.79 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID949 | TLDPERLG | Complement C3 | Plasma | 450.73 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID950 | EGVQKEDIPPADLSDQVPDTESETR | Complement C3 | Plasma | 919.09 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID951 | EGVQKEDIPPADLS | Complement C3 | Plasma | 749.37 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID952 | LDVSLQLPSR | Complement C3 | Plasma | 564.32 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID1039 | HWESASLL | Complement C3f | Serum | 942.44 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For Breast (Lower) and for Bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) = 1.74, 5.18 and 0.58 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1040 | IHWESASLL | Complement C3f | Serum | 1055.6 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 227, 1051 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1041 | RIHWESASLL | Complement C3f | Serum | 1211.7 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =7.86, 10.8 and 0.01 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1042 | HRIHWESASLL | Complement C3f | Serum | 1348.7 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | NA | 16395409 |
| CancerPDF_ID1043 | THRIHWESASLL | Complement C3f | Serum | 1449.76 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For Prostate & bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1885, 2646 and 437 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1044 | ITHRIHWESASLL | Complement C3f | Serum | 1562.84 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.79, 1.13 and 0.54 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1045 | KITHRIHWESASLL | Complement C3f | Serum | 1690.9 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For Prostate & bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =4.05, 6.85 and 1.01 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1046 | SKITHRIHWESASLL | Complement C3f | Serum | 1777.94 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For Prostate & bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =4.37, 7.7 and 0.96 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1047 | SSKITHRIHWESASLL | Complement C3f | Serum | 1864.95 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For Prostate & bladder (Higher) and for breast (Lower) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =2.18, 3.33 and 0.3 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1048 | SSKITHRIHWESASLLR | Complement C3f | Serum | 2021.06 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | NA | 16395409 |
| CancerPDF_ID1049 | SSKITHRIHWESASL | Complement C3f | Serum | 1751.88 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.82, 5.7 and 1.36 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1457 | ASHLGLAR | Complement C3 | Serum | 823.46644 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1458 | SVQLTEKR | Complement C3 | Serum | 959.53999 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1459 | WESASLLR | Complement C3 | Serum | 960.50288 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1460 | IHWESASLL | Complement C3 | Serum | 1054.54475 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1461 | SVQLTEKRM | Complement C3 | Serum | 1090.58048 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1462 | IPIEDGSGEVVLSRK | Complement C3 | Serum | 1597.86754 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1463 | TLDPERLGR | Complement C3 | Serum | 1055.57236 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1464 | GYTQQLAFR | Complement C3 | Serum | 1082.55089 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1465 | IEDGSGEVVLSR | Complement C3 | Serum | 1259.63574 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1466 | RIPIEDGSGEVVLS | Complement C3 | Serum | 1469.77257 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1467 | SPMYSIITPNILR | Complement C3 | Serum | 1503.81194 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1468 | SEETKENEGFTVTAEGK | Complement C3 | Serum | 1854.84832 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1469 | LSINTHPSQKPLSITVR | Complement C3 | Serum | 1890.0687 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1470 | SNLDEDIIAEENIVSR | Complement C3 | Serum | 1815.88504 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1471 | SSKITHRIHWESASLL | Complement C3 | Serum | 1863.99553 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1472 | ILLQGTPVAQMTEDAVDAERLK | Complement C3 | Serum | 2397.25736 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1473 | SEETKENEGFTVTAEGKGQGTLSVVTMYHAK | Complement C3 | Serum | 3327.5929 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1474 | EGVQKEDIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERL | Complement C3 | Serum | 5005.43501 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1475 | QGALELIK | Complement C3 | Serum | 870.51747 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1476 | TGLQEVEVK | Complement C3 | Serum | 1001.53933 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1477 | VLLDGVQNPR | Complement C3 | Serum | 1109.61931 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1478 | RQGALELIKK | Complement C3 | Serum | 1154.71354 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1479 | QPSSAFAAFVKR | Complement C3 | Serum | 1307.69862 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1480 | TKKQELSEAEQATR | Complement C3 | Serum | 1617.83221 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1481 | RIPIEDGSGEVVLSR | Complement C3 | Serum | 1625.87368 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1482 | QPSSAFAAFVK | Complement C3 | Serum | 1151.59751 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1483 | SVQLTEKRMD | Complement C3 | Serum | 1205.60742 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1484 | QELSEAEQATR | Complement C3 | Serum | 1260.59461 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1485 | EDGSGEVVLSRK | Complement C3 | Serum | 1274.64664 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1486 | IEDGSGEVVLSRK | Complement C3 | Serum | 1387.73071 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1487 | SSKITHRIHWESASLLR | Complement C3 | Serum | 2020.09664 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1488 | VPVAVQGEDTVQSLTQGDGVAK | Complement C3 | Serum | 2197.12264 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1489 | GYTQQLAFRQPSSAFAAFVK | Complement C3 | Serum | 2216.13784 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1490 | AGDFLEANYMNLQR | Complement C3 | Serum | 1640.76169 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1491 | SGIPIVTSPYQIHFT | Complement C3 | Serum | 1658.86681 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1492 | SEETKENEGFTVTAEG | Complement C3 | Serum | 1726.75335 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1493 | NLDEDIIAEENIVSR | Complement C3 | Serum | 1728.85301 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1494 | VPVAVQGEDTVQSLTQGDGVA | Complement C3 | Serum | 2069.02768 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1495 | ILLQGTPVAQMTEDAVDAERL | Complement C3 | Serum | 2269.1624 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1496 | EGVQKEDIPPADLSDQVPDTESETR | Complement C3 | Serum | 2754.28318 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1497 | FGLEKR | Complement C3 | Serum | 748.42317 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1498 | LLDGVQNPR | Complement C3 | Serum | 1010.55089 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1499 | RQGALELIK | Complement C3 | Serum | 1026.61858 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1500 | ELSEAEQATR | Complement C3 | Serum | 1132.53603 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1501 | AAVYHHFISDG | Complement C3 | Serum | 1215.56727 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1502 | YHHFISDGVR | Complement C3 | Serum | 1229.59415 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1503 | VYHHFISDGVR | Complement C3 | Serum | 1328.66257 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1504 | KQELSEAEQATR | Complement C3 | Serum | 1388.68957 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1505 | AVYHHFISDGVR | Complement C3 | Serum | 1399.69968 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1506 | LTQSKIWDVVEK | Complement C3 | Serum | 1444.79258 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1507 | AAVYHHFISDGVRK | Complement C3 | Serum | 1598.83176 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1508 | NKLTQSKIWDVVEK | Complement C3 | Serum | 1686.93047 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1509 | LSINTHPSQKPLSITV | Complement C3 | Serum | 1733.96758 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1510 | RIPIEDGSGEVVLSRK | Complement C3 | Serum | 1753.96865 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1511 | QGALELIKK | Complement C3 | Serum | 998.61243 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1512 | SVQLTEKRMD | Complement C3 | Serum | 1221.60234 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1513 | KQELSEAEQAT | Complement C3 | Serum | 1232.58846 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1514 | KVLLDGVQNPR | Complement C3 | Serum | 1237.71427 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1515 | SGSDEVQVGQQR | Complement C3 | Serum | 1288.60076 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1516 | IPIEDGSGEVVLS | Complement C3 | Serum | 1313.67146 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1517 | GQGTLSVVTMYHA | Complement C3 | Serum | 1362.66019 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1518 | TKKQELSEAEQAT | Complement C3 | Serum | 1461.7311 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1519 | IPIEDGSGEVVLSR | Complement C3 | Serum | 1469.77257 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1520 | LSINTHPSQKPLSITVRT | Complement C3 | Serum | 1991.11637 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1521 | DFLEANYMNLQR | Complement C3 | Serum | 1512.70311 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1522 | SPMYSIITPNILR | Complement C3 | Serum | 1519.80685 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1523 | SNLDEDIIAEENIVS | Complement C3 | Serum | 1659.78393 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1524 | SGIPIVTSPYQIHFTK | Complement C3 | Serum | 1786.96177 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1525 | IRAYYENSPQQVFSTEFEVK | Complement C3 | Serum | 2434.18049 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1526 | VAVQGEDTVQSLTQGDGVAK | Complement C3 | Serum | 2001.00146 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1527 | IHWESASL | Complement C3 | Serum | 941.46068 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1528 | SLKVVPEGIR | Complement C3 | Serum | 1096.66044 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1529 | GPLLNKFLTTA | Complement C3 | Serum | 1173.67576 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1530 | GPLLNKFLTTAKD | Complement C3 | Serum | 1416.79767 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1531 | YTQQLAFR | Complement C3 | Serum | 1025.52943 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1532 | IEDGSGEVVLS | Complement C3 | Serum | 1103.53463 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1533 | AAVYHHFISDGV | Complement C3 | Serum | 1314.63569 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1534 | AAVYHHFISDGVR | Complement C3 | Serum | 1470.7368 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1535 | AGDFLEANYMNLQ | Complement C3 | Serum | 1484.66058 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1536 | GDFLEANYMNLQR | Complement C3 | Serum | 1569.72458 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1537 | VLLDGVQNPRAEDLVGK | Complement C3 | Serum | 1821.99486 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1538 | SGQSEDRQPVPGQQMTLK | Complement C3 | Serum | 1984.96364 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1539 | TLDPERLGREGVQKEDIPPADLSDQVPDTESETR | Complement C3 | Serum | 3791.84497 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1540 | VAVQGEDTVQSLTQGDGVA | Complement C3 | Serum | 1872.9065 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1541 | EDGSGEVVLSR | Complement C3 | Serum | 1146.55168 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1542 | MYSIITPNILR | Complement C3 | Serum | 1319.72714 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1543 | NLDEDIIAEENIVS | Complement C3 | Serum | 1572.7519 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1544 | SSLSVPYVIVPLKTGLQEVEVK | Complement C3 | Serum | 2384.35666 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1545 | GYTQQLAFRQPSSAFAAFV | Complement C3 | Serum | 2088.04287 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1546 | SEFPESWLWNVEDLKEPPKNGIST | Complement C3 | Serum | 2801.35483 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1547 | SVQLTEK | Complement C3 | Serum | 803.43888 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1548 | SDDKVTLEERLD | Complement C3 | Serum | 1418.6889 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1549 | IFTVNHKLLPVGR | Complement C3 | Serum | 1492.88782 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1550 | AVYHHFISDGVRK | Complement C3 | Serum | 1527.79465 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1551 | GIPIVTSPYQIHFT | Complement C3 | Serum | 1571.83478 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1552 | QKPDGVFQEDAPVIHQEMIGGL | Complement C3 | Serum | 2407.1842 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1553 | TMQALPYSTVGNSNNYLHLSVLR | Complement C3 | Serum | 2577.30096 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1554 | YFKPGMPFDLMVFVTNPDGSPAY | Complement C3 | Serum | 2592.2069 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1555 | HWESASLL | Complement C3 | Serum | 941.46068 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2647 | LKGPLLN | Complement C3 | Plasma | 753.4749 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2648 | SSAFAAFV | Complement C3 | Plasma | 798.3912 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2649 | LDPERLG | Complement C3 | Plasma | 798.4236 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2650 | SSKITHR | Complement C3 | Plasma | 827.4614 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2651 | IFTVNHK | Complement C3 | Plasma | 857.4759 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2652 | QGALELIK | Complement C3 | Plasma | 870.5175 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2653 | NEQVEIR | Complement C3 | Plasma | 886.4508 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2654 | IWDVVEK | Complement C3 | Plasma | 887.4753 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2655 | HHFISDGV | Complement C3 | Plasma | 910.4297 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2656 | VGKYPKEL | Complement C3 | Plasma | 932.5331 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2657 | SLKVVPEGI | Complement C3 | Plasma | 940.5593 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2658 | QGALELIKK | Complement C3 | Plasma | 998.6124 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2659 | LLNKFLTTA | Complement C3 | Plasma | 1019.6015 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2660 | QPSSAFAAFV | Complement C3 | Plasma | 1023.5026 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2661 | IHWESASLL | Complement C3 | Plasma | 1054.5448 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2662 | TLDPERLGR | Complement C3 | Plasma | 1055.5724 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2663 | YHHFISDGV | Complement C3 | Plasma | 1073.493 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2664 | GYTQQLAFR | Complement C3 | Plasma | 1082.5509 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2665 | SLKVVPEGIR | Complement C3 | Plasma | 1096.6604 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2666 | HWESASLLR | Complement C3 | Plasma | 1097.5618 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2667 | KVLLDGVQNL | Complement C3 | Plasma | 1097.6445 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2668 | VQLTEKRMD | Complement C3 | Plasma | 1118.5754 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2669 | KAGDFLEANY | Complement C3 | Plasma | 1126.5295 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2670 | VYHHFISDGV | Complement C3 | Plasma | 1172.5615 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2671 | GPLLNKFLTTA | Complement C3 | Plasma | 1173.6758 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2672 | SVQLTEKRMD | Complement C3 | Plasma | 1205.6074 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2673 | IHWESASLLR | Complement C3 | Plasma | 1210.6459 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2674 | KQELSEAEQAT | Complement C3 | Plasma | 1232.5885 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2675 | RHQQTVTIPPK | Complement C3 | Plasma | 1303.7361 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2676 | IPIEDGSGEVVLS | Complement C3 | Plasma | 1313.6715 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2677 | AAVYHHFISDGV | Complement C3 | Plasma | 1314.6357 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2678 | MYSIITPNILR | Complement C3 | Plasma | 1319.7271 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2679 | SVQLTEKRMDK | Complement C3 | Plasma | 1333.7024 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2680 | GQGTLSVVTMYHA | Complement C3 | Plasma | 1362.6602 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2681 | IEDGSGEVVLSRK | Complement C3 | Plasma | 1387.7307 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2682 | AVYHHFISDGVR | Complement C3 | Plasma | 1399.6997 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2683 | LTQSKIWDVVEK | Complement C3 | Plasma | 1444.7926 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2684 | TKKQELSEAEQAT | Complement C3 | Plasma | 1461.7311 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2685 | IPIEDGSGEVVLSR | Complement C3 | Plasma | 1469.7726 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2686 | RIPIEDGSGEVVLS | Complement C3 | Plasma | 1469.7726 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2687 | AAVYHHFISDGVR | Complement C3 | Plasma | 1470.7368 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2688 | VVLVAVDKGVFVLN | Complement C3 | Plasma | 1470.881 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2689 | AGDFLEANYMNLQ | Complement C3 | Plasma | 1484.6606 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2690 | SPMYSIITPNILR | Complement C3 | Plasma | 1503.8119 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2691 | AVLYNYRQNQEL | Complement C3 | Plasma | 1509.7576 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2692 | SDDKVTLEERLDK | Complement C3 | Plasma | 1546.7839 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2693 | GIPIVTSPYQIHFT | Complement C3 | Plasma | 1571.8348 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2694 | TLDPERLGREGVQK | Complement C3 | Plasma | 1596.8584 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2695 | IPIEDGSGEVVLSRK | Complement C3 | Plasma | 1597.8675 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2696 | AAVYHHFISDGVRK | Complement C3 | Plasma | 1598.8318 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2697 | TKKQELSEAEQATR | Complement C3 | Plasma | 1617.8322 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2698 | AGDFLEANYMNLQR | Complement C3 | Plasma | 1640.7617 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2699 | SGIPIVTSPYQIHFT | Complement C3 | Plasma | 1658.8668 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2700 | TELRPGETLNVNFLL | Complement C3 | Plasma | 1714.9254 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2701 | LSINTHPSQKPLSITV | Complement C3 | Plasma | 1733.9676 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2702 | RIPIEDGSGEVVLSRK | Complement C3 | Plasma | 1753.9686 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2703 | SGIPIVTSPYQIHFTK | Complement C3 | Plasma | 1786.9618 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2704 | SNLDEDIIAEENIVSR | Complement C3 | Plasma | 1815.885 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2705 | SEETKENEGFTVTAEGK | Complement C3 | Plasma | 1854.8483 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2706 | SGQSEDRQPVPGQQMTL | Complement C3 | Plasma | 1856.8687 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2707 | SSKITHRIHWESASLL | Complement C3 | Plasma | 1863.9955 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2708 | TELRPGETLNVNFLLR | Complement C3 | Plasma | 1871.0265 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2709 | VAVQGEDTVQSLTQGDGVA | Complement C3 | Plasma | 1872.9065 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2710 | EYVLPSFEVIVEPTEK | Complement C3 | Plasma | 1877.9662 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2711 | SGQSEDRQPVPGQQMTLK | Complement C3 | Plasma | 1984.9636 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2712 | LSINTHPSQKPLSITVRT | Complement C3 | Plasma | 1991.1164 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2713 | VAVQGEDTVQSLTQGDGVAK | Complement C3 | Plasma | 2001.0015 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2714 | SSKITHRIHWESASLLR | Complement C3 | Plasma | 2020.0966 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2715 | VPVAVQGEDTVQSLTQGDGVA | Complement C3 | Plasma | 2069.0277 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2716 | GYTQQLAFRQPSSAFAAFV | Complement C3 | Plasma | 2088.0429 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2717 | SGIPIVTSPYQIHFTKTPK | Complement C3 | Plasma | 2113.1572 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2718 | ILLQGTPVAQMTEDAVDAER | Complement C3 | Plasma | 2156.0783 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2719 | VPVAVQGEDTVQSLTQGDGVAK | Complement C3 | Plasma | 2197.1226 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2720 | GYTQQLAFRQPSSAFAAFVK | Complement C3 | Plasma | 2216.1378 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2721 | SSLSVPYVIVPLKTGLQEVEV | Complement C3 | Plasma | 2256.2617 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2722 | ILLQGTPVAQMTEDAVDAERL | Complement C3 | Plasma | 2269.1624 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2723 | IRAYYENSPQQVFSTEFEV | Complement C3 | Plasma | 2306.0855 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2724 | SEFPESWLWNVEDLKEPPK | Complement C3 | Plasma | 2329.1267 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2725 | SSLSVPYVIVPLKTGLQEVEVK | Complement C3 | Plasma | 2384.3567 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2726 | QKPDGVFQEDAPVIHQEMIGGL | Complement C3 | Plasma | 2407.1842 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2727 | TMQALPYSTVGNSNNYLHLSVL | Complement C3 | Plasma | 2421.1998 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2728 | IRAYYENSPQQVFSTEFEVK | Complement C3 | Plasma | 2434.1805 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2729 | EGVQKEDIPPADLSDQVPDTESETR | Complement C3 | Plasma | 2754.2832 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2730 | SEFPESWLWNVEDLKEPPKNGIST | Complement C3 | Plasma | 2801.3548 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2731 | AEDLVGKSLYVSATVILHSGSDMVQAER | Complement C3 | Plasma | 2974.507 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2732 | LESEETMVLEAHDAQGDVPVTVTVHDFPG | Complement C3 | Plasma | 3121.455 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2733 | SEETKENEGFTVTAEGKGQGTLSVVTMYHA | Complement C3 | Plasma | 3199.4979 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2734 | SEETKENEGFTVTAEGKGQGTLSVVTMYHA | Complement C3 | Plasma | 3215.4928 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2735 | LESEETMVLEAHDAQGDVPVTVTVHDFPGK | Complement C3 | Plasma | 3249.55 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2736 | LMNIFLKDSITTWEILAVSMSDKKGICVA | Complement C3 | Plasma | 3257.675 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2737 | SEETKENEGFTVTAEGKGQGTLSVVTMYHAK | Complement C3 | Plasma | 3327.5929 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2738 | TLDPERLGREGVQKEDIPPADLSDQVPDTESET | Complement C3 | Plasma | 3635.7439 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2739 | TLDPERLGREGVQKEDIPPADLSDQVPDTESETR | Complement C3 | Plasma | 3791.845 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3258 | SKITHRIHWESASLL | Complement C3f | Serum | 1534 | MALDI-TOF | Stomach adenocarcinoma | NA | 21267442 |
| CancerPDF_ID3747 | DFVPPVVRWLNEQRYYGGGY | Complement C3 | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID4105 | ADIGCTPGSGKDYAGVF | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4407 | AVHYLDETEQWEKF | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4576 | DFWGEKPNLSYI | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4634 | DLMVFVTNPDGSPAYRVPV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4635 | DLMVFVTNPDGSPAYRVPVAV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4960 | FLKDSITTWEI | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5223 | GLSSDFWGEKPNLSYI | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5284 | GRLKGPLLNKF | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5414 | IAIDSQVLCGAVKW | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5415 | IAIDSQVLCGAVKWL | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5616 | KQDSLSSQNQLGVLPLSWDIPELV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5907 | LLDGVQNPRAEDLVGKSLYV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5987 | LPLSITTDFIPSFRLV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6020 | LQLKDFDFVPPVVRWLNEQ | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6077 | LSSDFWGEKPNLSYI | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6237 | MVNIENPEGIPVKQDSLSSQNQLGVLPLSWDIPELV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6380 | NYMNLQRSYTV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6495 | QDFFIDLRLPYSVV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6547 | QLKDFDFVPPVVRWLNEQ | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6552 | QLSNDFDEYIMAIEQTI | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6648 | REPGQDLVVLPLSITTDFIPSFRLV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6649 | REPGQDLVVLPLSITTDFIPSFRLVA | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6777 | SDAGLTFTSSSGQQTAQRAELQCPQPAA | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6951 | SITTDFIPSFRLV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7071 | SRSEFPESWLWNV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7072 | SRSEFPESWLWNVEDL | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7124 | SSQNQLGVLPLSWDIPELV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7579 | TTDFIPSFRLV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7836 | VFVTNPDGSPAYRVPV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7908 | VLPLSITTDFIPSFRLV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7909 | VLPLSITTDFIPSFRLVA | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8007 | VSRSEFPESWLWNV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8363 | YSIITPNILRLESEETM | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8544 | SSKITHRIHWESASLLR | Complement C3f | Serum | 2020.1 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8545 | SKITHRIHWE | Complement C3f | Serum | 1305.69 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8546 | SKITHRIHWESASLL | Complement C3f | Serum | 1776.96 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8547 | KITHRIHWESASLL | Complement C3f | Serum | 1689.93 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8548 | THRIHWESASLL | Complement C3f | Serum | 1448.75 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8549 | THRIHWE | Complement C3f | Serum | 977.48 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8550 | HRIHWESASLL | Complement C3f | Serum | 1347.7 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8551 | IHWESASLL | Complement C3f | Serum | 1054.54 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8552 | HWESASLL | Complement C3f | Serum | 941.46 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8553 | HWESASLL | Complement C3f | Serum | 955.48 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8554 | HWESASL | Complement C3f | Serum | 828.38 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8555 | ASHLGLA | Complement C3f | Serum | 667.37 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8556 | SEETKENEGFTVTAEGK | Complement C3f | Serum | 1854.85 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8557 | RNGFKSHALQLNNRQI | Complement C3f | Serum | 1895.02 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8558 | NGFKSHALQLNNR | Complement C3f | Serum | 1497.78 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8559 | SHALQLNN | Complement C3f | Serum | 895.45 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8560 | GLEEELQFSLGSKINVKVGGNSKGTLKVLR | Complement C3f | Serum | 3199.79 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8561 | GLEEELQFSLGSKINVKVGGNSKGTL | Complement C3f | Serum | 2703.44 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8562 | GLEEELQFSLGSKINVKVGGNS | Complement C3f | Serum | 2304.2 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8563 | DDPDAPLQPVTPLQLFEGRRN | Complement C3f | Serum | 2377.2 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8677 | ADLSDQVPDTES | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8678 | ADLSDQVPDTESETR | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8729 | CCEDGMRENPM | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8760 | DLSDQVPDTES | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8761 | DLSDQVPDTESETR | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8784 | EDIPPADLSD | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8785 | EDIPPADLSDQVPDTES | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8786 | EETKENEGFTVTAEG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8788 | EGFTVTAEGKGQG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8789 | EGFTVTAEGKGQGTLS | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8804 | ENPMRFSCQ | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8816 | ETKENEGFTVTAEG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8830 | FISLGEAC | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8831 | FLDCCNYITEL | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8852 | FTVTAEGKGQGTLS | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8861 | GEACKKVFLDCCNY | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8904 | GQGTLSVVTMYH | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8922 | GTPVAQMTEDAVDAER | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8940 | HLIVTPSGCGEQ | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8948 | HYLDETEQWEK | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8977 | IPPADLSDQVPDTESE | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8978 | IPPADLSDQVPDTESET | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8979 | IPPADLSDQVPDTESETRILL | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8980 | IPPADLSDQVPDTESETRILLQ | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8981 | IPPADLSDQVPDTESETRILLQG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9007 | KVFLDCCNYITEL | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9009 | LDCCNYITELR | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9034 | LIVTPSGCGEQ | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9099 | NLDVSLQLPS | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9132 | PADLSDQVPDTESETR | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9137 | PPADLSDQVPDTES | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9138 | PPADLSDQVPDTESET | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9139 | PPADLSDQVPDTESETR | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9140 | PPADLSDQVPDTESETRILLQG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9210 | RFISLGEAC | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9221 | SDQVPDTESETRILLQG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9224 | SEETKENEGFTVTAE | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9225 | SEETKENEGFTVTAEGKG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9226 | SEETKENEGFTVTAEGKGQG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9227 | SEETKENEGFTVTAEGKGQGTLS | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9288 | TEDAVDAERL | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9309 | TLSVVTMYH | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9318 | TPVAQMTEDAVDAER | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9319 | TPVAQMTEDAVDAERL | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9320 | TPVAQMTEDAVDAERLK | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9328 | TRFISLGEAC | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9361 | VFLDCCNY | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9362 | VFLDCCNYITE | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9363 | VFLDCCNYITEL | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9397 | VPDTESETRILL | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9398 | VPDTESETRILLQG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9456 | HWESASLLR | Complement C3 | Plasma | 1098.57 | MALDI-TOF | Colorectal cancer | "Lower intensity in control, adenoma, early,late CRC and much more lower in liver metastasis group." | 26379225 |
| CancerPDF_ID9457 | THRIHWESA | Complement C3 | Plasma | 1136.57 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
| CancerPDF_ID9459 | IHWESASLLR | Complement C3 | Plasma | 1211.65 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
| CancerPDF_ID9461 | ITHRIHWESA | Complement C3 | Plasma | 1249.65 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
| CancerPDF_ID9464 | RIHWESASLLR | Complement C3 | Plasma | 1367.77 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
| CancerPDF_ID9465 | KITHRIHWESA | Complement C3 | Plasma | 1377.72 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
| CancerPDF_ID9468 | SKITHRIHWESA | Complement C3 | Plasma | 1464.77 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
| CancerPDF_ID9471 | SSKITHRIHWESA | Complement C3 | Plasma | 1551.82 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
| CancerPDF_ID9472 | THRIHWESASLLR | Complement C3 | Plasma | 1605.87 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
| CancerPDF_ID9474 | ITHRIHWESASLLR | Complement C3 | Plasma | 1718.95 | MALDI-TOF | Colorectal cancer | Similar intensity into the case groups. | 26379225 |
| CancerPDF_ID9475 | SKITHRIHWESASLL | Complement C3 | Plasma | 1777.98 | MALDI-TOF | Colorectal cancer | Higher than adenoma and CRC groups | 26379225 |
| CancerPDF_ID9477 | KITHRIHWESASLLR | Complement C3 | Plasma | 1847.04 | MALDI-TOF | Colorectal cancer | "Low expression in control, adenoma, early,late CRC and much more lower in liver metastasis group." | 26379225 |
| CancerPDF_ID9478 | SSKITHRIHWESASLL | Complement C3 | Plasma | 1865 | MALDI-TOF | Colorectal cancer | Similar intensity into the case groups. | 26379225 |
| CancerPDF_ID9482 | SKITHRIHWESASLLR | Complement C3 | Plasma | 1934.07 | MALDI-TOF | Colorectal cancer | "Low expression in control, adenoma, early,late CRC and much more lower in liver metastasis group." | 26379225 |
| CancerPDF_ID9483 | SSKITHRIHWESASLLR | Complement C3 | Plasma | 2021.1 | MALDI-TOF | Colorectal cancer | "Low expression in control, adenoma, early,late CRC and much more lower in liver metastasis group." | 26379225 |
| CancerPDF_ID9484 | SSKITHRIHWESASLLR | Complement C3 | Plasma | 2037.09 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
| CancerPDF_ID9485 | SSKITHRIHWE(Na)SASLLR | Complement C3 | Plasma | 2043.1 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
| CancerPDF_ID9486 | SSKITHRIHWE(K)SASLLR | Complement C3 | Plasma | 2059 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
| CancerPDF_ID9597 | IHWESASLL | Complement C3 | Serum | 528.26 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9598 | LDVSLQLPSR | Complement C3 | Serum | 564.34 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9599 | IHWESASLLR | Complement C3 | Serum | 404.55 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9600 | RIHWESASLLR | Complement C3 | Serum | 456.58 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9601 | TKENEGFTVTAEG | Complement C3 | Serum | 691.82 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9602 | EETKENEGFTVTAEG | Complement C3 | Serum | 820.86 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9603 | SEETKENEGFTVTAEG | Complement C3 | Serum | 864.35 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9604 | EETKENEGFTVTAEGK | Complement C3 | Serum | 590.26 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9605 | SEETKENEGFTVTAEGK | Complement C3 | Serum | 619.27 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9606 | HWESASLL | Complement C3 | Serum | 471.73 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9607 | SKITHRIHWESASLLR | Complement C3 | Serum | 484.28 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9608 | SSKITHRIHWESASLLR | Complement C3 | Serum | 506.03 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9609 | SVQLTEK | Complement C3 | Serum | 402.71 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9956 | DVSLQLPSR | Complement C3 | Urine | 1014.5541 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10066 | YSIITPNILRL | Complement C3 | Urine | 1302.7755 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10199 | ITHRIHWESASLL | Complement C3 | Urine | 1562.8365 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10307 | AQYQKDAPDHQELNL | Complement C3 | Urine | 1769.8455 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10382 | IKKGYTQQLAFRQPSSA | Complement C3 | Urine | 1923.0429 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10435 | LIKKGYTQQLAFRQPSSA | Complement C3 | Urine | 2036.1576 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10447 | IKKGYTQQLAFRQPSSAF | Complement C3 | Urine | 2070.0923 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10539 | SEETKENEGFTVTAEGKGQGTL | Complement C3 | Urine | 2312.0743 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10607 | LRSEETKENEGFTVTAEGKGQGTL | Complement C3 | Urine | 2581.2753 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10624 | EAHDAQGDVPVTVTVHDFPGKKLVL | Complement C3 | Urine | 2672.4004 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID11072 | SPMYSIITPNILR | CO3_HUMAN | Serum | 1520.8456 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Differentially expressed between cancer vs normal | 27043541 |
| CancerPDF_ID11599 | HRIHWESASLL | Complement C3 | Serum | 1347.7048 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID11620 | HWESASL | Complement C3 | Serum | 828.37662 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID11621 | HWESASLL | Complement C3 | Serum | 941.46068 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID11622 | HWESASLLR | Complement C3 | Serum | 1097.5618 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID11972 | PERLGREGVQK | Complement C3 | Serum | 1267.6997 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID11973 | PERLGREGVQKED | Complement C3 | Serum | 1511.7692 | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12169 | SEETKENEGFTVTAEGK | Complement C3 | Serum | 1854.8483 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12198 | SKITHRIHWESASLL | Complement C3 | Serum | 1776.9635 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12274 | SSKITHRIHWESASLL | Complement C3 | Serum | 1863.9955 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12339 | SVQLTEKRMD | Complement C3 | Serum | 1205.6074 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12431 | THRIHWESAS | Complement C3 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12432 | THRIHWESASLL | Complement C3 | Serum | 1448.7524 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12439 | TKENEGFTVTAEGK | Complement C3 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12521 | TVQSLTQGD | Complement C3 | Serum | 947.45599 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12593 | VPVTVTVHD | Complement C3 | Serum | NA | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12671 | SVQLTEKRMD | Complement C3 | Serum | NA | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12695 | HRIHWE | Complement C3 | Serum | 877.0667 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.19 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.25, Upregulated in BC vs healthy with 1.065 fold change" | 27058005 |
| CancerPDF_ID12696 | IHWESASLL | Complement C3 | Serum | 1055.082 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.21 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.27, Upregulated in BC vs healthy with 1.126 fold change" | 27058005 |
| CancerPDF_ID12697 | SSKITHRIH | Complement C3 | Serum | 1078.125 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.03 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.19, Upregulated in BC vs healthy with 1.006 fold change" | 27058005 |
| CancerPDF_ID12698 | SVQLTEKRMD | Complement C3 | Serum | 1206.7 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.02 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.13, Upregulated in BC vs healthy with 1.024 fold change" | 27058005 |
| CancerPDF_ID12699 | RIHWESASLL | Complement C3 | Serum | 1211.694 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.17 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.22, Upregulated in BC vs healthy with 1.157 fold change" | 27058005 |
| CancerPDF_ID12700 | HRIHWESASLL | Complement C3 | Serum | 1348.755 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.59 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.13, Upregulated in BC vs healthy with 1.042 fold change" | 27058005 |
| CancerPDF_ID12701 | THRIHWESASLL | Complement C3 | Serum | 1449.804 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.52 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.25, Upregulated in BC vs healthy with 1.134 fold change" | 27058005 |
| CancerPDF_ID12702 | SKITHRIHWESAS | Complement C3 | Serum | 1551.893 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.18 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.17, Upregulated in BC vs healthy with 1.156 fold change" | 27058005 |
| CancerPDF_ID12703 | ITHRIHWESASLL | Complement C3 | Serum | 1562.888 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.30 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.22, Upregulated in BC vs healthy with 1.134 fold change" | 27058005 |
| CancerPDF_ID12704 | SVQLTEKRMDKVGK | Complement C3 | Serum | 1634.944 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.95 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.04, Upregulated in BC vs healthy with 1.049 fold change" | 27058005 |
| CancerPDF_ID12705 | KITHRIHWESASLL | Complement C3 | Serum | 1690.987 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 2.19 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.36, Upregulated in BC vs healthy with 1.341 fold change" | 27058005 |
| CancerPDF_ID12706 | SKITHRIHWESASLL | Complement C3 | Serum | 1778.018 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 2.10 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.37, Upregulated in BC vs healthy with 1.343 fold change" | 27058005 |
| CancerPDF_ID12707 | KITHRIHWESASLLR | Complement C3 | Serum | 1847.095 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.26 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.30, Upregulated in BC vs healthy with 1.623 fold change" | 27058005 |
| CancerPDF_ID12708 | SSKITHRIHWESASLL | Complement C3 | Serum | 1865.05 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 2.06 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.35, Upregulated in BC vs healthy with 1.344 fold change" | 27058005 |
| CancerPDF_ID12709 | SSKITHRIHWESASLLR | Complement C3 | Serum | 2021.146 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.02 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.19, Upregulated in BC vs healthy with 1.844 fold change" | 27058005 |